# Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

> **NCT05008536** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 27 (estimated)

## Conditions studied

- Multiple Myeloma, Refractory

## Interventions

- **BIOLOGICAL:** Anti-BCMA CAR-NK Cells
- **DRUG:** Fludarabine
- **DRUG:** Cytoxan

## Key facts

- **NCT ID:** NCT05008536
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05008536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05008536, "Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05008536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*